Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026)

Protalix BioTherapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Raw Materials rose 33.97% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 33.97% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 31.46% from the prior year.
• Raw Materials held at $6.0 million in Q1 2026 per PLX's latest filing, from $6.0 million in the prior quarter.
• Across five years, Raw Materials topped out at $6.0 million in Q1 2026 and bottomed at $3.1 million in Q1 2022.
• The 5-year median for Raw Materials is $4.3 million (2024), against an average of $4.3 million.
• Across the five-year window, Raw Materials decreased 10.53% in 2022 and surged 40.51% in 2023, its largest moves.
• Year by year, Raw Materials stood at $3.5 million in 2022, then increased by 19.04% to $4.2 million in 2023, then advanced by 8.93% to $4.5 million in 2024, then jumped by 31.46% to $6.0 million in 2025, then gained by 0.45% to $6.0 million in 2026.
• Per Business Quant, the three latest PLX Raw Materials figures stand at $6.0 million (Q1 2026), $6.0 million (Q4 2025), and $5.0 million (Q3 2025).